Provincial Health Services Authority

Systemic Therapy Update

Volume 29 Issue 11
November 2026

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice
Influenza and Respiratory Illness Vaccines
New Programs
- **UBRAVIPBFL** Inavolisib, Palbociclib and Fulvestrant with or without LHRH Agonist for Advanced Breast Cancer
- **GIGAVTW** Weekly Paclitaxel for Second-Line Treatment of Advanced Esophageal/GEJ Squamous Cell Carcinoma

Expansion of Existing Programs
- **GOCABRBEV → GOCXCPNB, GOOVCPNB** Alternative Treatment of Cervical or Ovarian Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB
- **LKCMLA** Asciminib for Chronic Myeloid Leukemia

Drug Update
- Pembrolizumab Shorter Duration Infusion
- Gemcitabine in D5W to Reduce Vein Irritation
- Etoposide Capsule Storage

Practice Standards and Policies
- Dose Banding Update: Paclitaxel NAB

Cancer Drug Manual©
New inavolisib, interim: balstilimab, botensilimab
Revised epcoritamab, etoposide, gemcitabine, goserelin, leuprolide, pembrolizumab
Auxiliary Label List etoposide, inavolisib
Extravasation Hazard Table amivantamab, nivolumab-relatlimab, tremelimumab, zolbetuximab
Lactose Intolerance: Dispensing Oral Medications

Continuing Education
FPON Webinar Managing Menopause in Patients with Hormone-Sensitive Cancers

Benefit Drug List
New UBRAVIPBFL, GIGAVTW, GOCXCPNB, GOOVCPNB

Protocols, PPPOs and Patient Handouts
New **BR** BRAJPEM6, UBRAVIPBFL **GI** GIGAVTW **GO** GOCXCPNB, GOOVCPNB **SA** SAIME
Revised **BR** BRAJPEM, BRAJPEM6, BRAJPN, BRAJPNCT, BRAJPNT, BRAVABR, UBRAVCAFLV, BRAVEVEX, BRAVGEM, BRAVGEMD, BRAVGEMP, BRAVGEMT, BRAVLUENH, BRAVPALAI, BRAVPBFLV, BRAVPEM, BRAVPEM6, BRAVPGC, BRAVPP, BRAVPPN, BRAVRBFLV, BRAVRIBAI, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG, BRPCTAC, BRPCWTAC **CN** UCNVORA **GI** GIAVDURPG, GIAVPEM, GIAVPEM6, GIAVPEMPG, GIAVPG, GIGAVCOXP, GIGAVFFOXP, GIGAVPCOXT, GIGAVPFOXT, GIPAJGCAP, GIPAJGEM, GIPGEM, GIPGEMABR **GO** GOCABR, GOCABRBEV, GOCXCPNBP, GOCXCPNP, GOEAVDPNC, GOEAVPPNC, GOOVBEVG, GOOVCAG, GOOVGEM, GOSADG **GU** GUAJPEM, GUAJPEM6, GUAJPG, GUAVEVPEM, GUAVPEM, GUAVPEM6, GUAVPEMAX, GUAVPEMAX6, GUAVPEML, GUAVPEML6, GUAVPG, GUBGEM, GUBGEMDOC, GUBGRT, GUBNADURPG, GUNAJPG, UGUPLVT, GUTAXGEM **HN** HNNAVGEM, HNNAVPG, HNNLAPG **LK** LKCMLA, LKCMLB, LKCMLD, LKCMLN **LU** LUAJPMB, LUAJPMB6, LUAVPCPMB, LUAVPG, LUAVPGCEM, LUAVPGDT, LUAVPGPMB, LUAVPMB, LUAVPMB6, LUAVPMBF, LUAVPMBF6, LUAVPMBM, LUAVPMBM6, LUAVPPMBM, LUAVPPPMB, LUMMPG, LUMMPPPMB, LUNAPGPMB, LUNAPPPMB, LUSCPEPO, LUSCPEPORT, LUSCPOE **LY** LYBV, LYDHAPR, LYGDP, LYGDPO, LYGDPR, LYGEMOXPEG, LYGVLD, ULYOGGEMOX, LYRICE **MY** UMYTEC **SA** SAAVGEM, SAAVGEMD, SAAVVIT, SAAVVPOIT, SAIME **SM** SMAJDT, SMAVDAB, SMAVIPNI

Resources and Contact Information

Editor's Choice

Influenza and Respiratory Illness Vaccine Recommendations

The **BC Cancer Influenza Vaccine Recommendations for Adults with Cancer** have been updated for the 2026-2027 influenza season. Patients should be offered an age-appropriate **inactivated influenza vaccine** (trivalent inactivated influenza vaccine for adults under 65 years of age, and adjuvanted trivalent inactivated influenza vaccine for all adults 65 years of age and older). The recommendations are available in the Cancer Management Manual and in the Chemotherapy Protocols section of the BC Cancer website.

…continued over

Editor's Choice

The BC Cancer webpage **Respiratory Illness and COVID-19 Vaccine Information for People with Cancer** is being updated and includes information on **influenza**, **RSV** and **COVID-19**.

Health professionals can find information on RSV and COVID-19 vaccine eligibility on the BC Centre for Disease Control (BCCDC) website:

- **RSV vaccine** | **BCCDC RSV Vaccine Q and A**
  - a single dose is recommended and publicly funded in all adults 75 years of age and older, as well as First Nations, Métis, and Inuit (Indigenous) individuals 60 years of age and older
  - the RSV vaccine is also recommended in adults 65 to 74 years of age who are at increased risk of severe RSV disease (including patients with solid tumours or hematologic malignancies); this is not publicly funded but patients may have third-party coverage
- **COVID-19 vaccine** | **BCCDC COVID-19 Vaccine Eligibility**
  - one dose is recommended in the fall vaccine program for severely immunocompromised patients (including patients with solid tumours or hematologic malignancies); further information will be released in the spring as to eligibility for an additional dose

Information on recommended vaccines and immunization principles in patients with solid tumours and hematologic malignancies can be found on the BCCDC and Canadian Immunization Guide websites:

- BCCDC | Patients with Malignant Neoplasm
- BCCDC | Patients on Immunosuppressive Therapy
- Canadian Immunization Guide | Immunization of Immunocompromised Persons

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 November 2026. Full details of all treatment programs are available in the **Chemotherapy Protocols** section of the BC Cancer website.

Breast

Inavolisib, Palbociclib and Fulvestrant with or without LHRH Agonist for Advanced Breast Cancer (UBRAVIPBFL) – The BC Cancer Breast Tumour Group is introducing treatment with inavolisib in combination with palbociclib and fulvestrant for patients with endocrine-resistant, *PIK3CA*-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer. Eligibility includes disease progression during or within 12 months of completing adjuvant endocrine therapy and no prior therapy for advanced disease. Inavolisib is a selective PI3K inhibitor and molecular testing for a *PIK3CA* mutation is required. Given the risk of treatment-related hyperglycemia, blood glucose levels should be optimized in all patients prior to treatment initiation. Close monitoring of fasting blood glucose is required throughout treatment, particularly during the first cycle. The treatment protocol includes the option of prophylactic metformin for patients with hyperglycemia risk factors as well as dexamethasone mouthwash for the prevention of stomatitis.

In the randomized, controlled, double-blind, phase III INAVO120 trial, the addition of inavolisib to palbociclib-fulvestrant significantly improved progression-free survival (PFS) compared with placebo plus palbociclib-fulvestrant.[1,2] The addition of inavolisib also improved objective response rate and demonstrated a favorable trend toward overall survival (OS). The most common adverse events associated with inavolisib included hyperglycemia, stomatitis and diarrhea.

Editor's Choice

Gastrointestinal

Weekly Paclitaxel for Second-Line Treatment of Advanced Esophageal and GEJ Squamous Cell Carcinoma (GIGAVTW) – The BC Cancer Gastrointestinal Tumour Group is implementing treatment with weekly paclitaxel for patients with locally advanced unresectable or metastatic esophageal or gastroesophageal junction (GEJ) squamous cell carcinoma (SCC) not amenable to curative-intent therapy. Eligibility includes disease progression following first-line treatment or not a candidate for first-line fluoropyrimidine plus platinum-based chemotherapy.

In a retrospective study of weekly paclitaxel or docetaxel given every 3 weeks in patients with advanced or recurrent esophageal SCC who previously received fluoropyrimidine- and platinum-based chemotherapy, the taxane regimens were similarly effective in terms of PFS and mOS.[3] Notably, treatment with weekly paclitaxel resulted in less toxicity with lower rates of febrile neutropenia and grade 3-4 neutropenia.

References:
1. Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in *PIK3CA*-mutated advanced breast cancer. *N Engl J Med* 2024;391:1584-1596. https://doi.org/10.1056/NEJMoa2404625
2. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Inavolisib (Itovebi®). *Canadian Journal of Health Technologies* 2025;5(12):1-37. https://doi.org/10.51731/cjht.2025.130
3. Shirakawa T, Kato K, Nagashima K, et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. *Cancer Chemother Pharmacol* 2014;74(6):1207-1215. https://doi.org/10.1007/s00280-014-2597-3

Expansion of Existing Programs

BC Cancer Provincial Systemic Therapy has approved expansion of the following treatment programs effective 01 November 2026.

Gynecologic Oncology

Alternative Treatment of Gynecologic Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB The BC Cancer Gynecologic Oncology Tumour Group is updating the GOCABRBEV protocol as well as introducing protocols specific for cervical cancer (GOCXCPNB) and ovarian cancer (GOOVCPNB). These updates will align bevacizumab dosing according to the tumour site being treated. New patients should be started on GOCXCPNB or GOOVCPNB. Existing patients should continue to use GOCABRBEV to complete treatment; GOCABRBEV will be retired once all active patients have completed treatment.

GOCABRBEV	→	**GOCXCPNB**	***Cervical cancer***
	→	**GOOVCPNB**	***Ovarian cancer***

Leukemia and BMT

Asciminib for Chronic Myeloid Leukemia (LKCMLA) – The BC Cancer Leukemia and BMT Tumour Group is expanding the eligibility criteria to include patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. The open-label, randomized, controlled, phase III ASC4FIRST trial compared asciminib to investigator-selected tyrosine kinase inhibitor (TKI) in the first-line treatment of CML in the chronic phase.[1,2] The asciminib group demonstrated faster and deeper molecular responses. More patients on asciminib remained on treatment, and there were fewer adverse events leading to treatment discontinuation, compared to investigator-selected TKI.

Editor's Choice

References:
1. Hochhaus A, Wang J, Kim D-W, et al. Asciminib in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2024;391(10):885-898. https://doi.org/10.1056/NEJMoa2400858
2. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Asciminib (Scemblix®). *Canadian Journal of Health Technologies* 2025;5(10):1-25. https://doi.org/10.51731/cjht.2025.1260

Drug Update

Pembrolizumab Shorter Duration Infusion

The BC Cancer standard for pembrolizumab administration has been a 30-minute intravenous (IV) infusion, based on the manufacturer product monograph. This duration was selected during drug development as a general measure to prevent infusion-related reactions (IRRs), despite limited pharmacological rationale.

Two recently published studies proposed a shorter duration 10-minute IV infusion as a safe and feasible alternative to enhance workflow efficiency and save chair time, without compromising clinical outcomes. Evaluating the transition from a 30-minute to a 10-minute IV infusion, both studies concluded that the shorter 10-minute infusion was safe, well-tolerated and time-efficient.

Starting **01 November 2026**, BC Cancer is **standardizing the pembrolizumab IV infusion duration to 10 minutes**. The 10-minute infusion will be initiated from cycle 1, given the low incidence of serious IRRs reported (< 1%). Affected treatment protocols, provincial preprinted orders (PPPOs), patient handouts and Cerner PowerPlans will be updated accordingly.

Implementation is being carried out in two phases, based on tumour site:

Implementation Date	Treatment protocols
01 November 2026	*Breast, Gastrointestinal, Genitourinary, Lung*
01 December 2026	*Gynecology, Head & Neck, Lymphoma, Skin & Melanoma, Tumour Agnostic*

References:
1. van Rijssen L, Nagtegaal IEC, Ploos van Amstel FK, et al. Safety of accelerated infusion of nivolumab and pembrolizumab. *Eur J Cancer* 2025;220. https://doi.org/10.1016/j.ejca.2025.115373
2. de Boer ECS, Fiebrich-Westra H-B, Lenis GMM, et al. Safety, feasibility, and patient experience of ten-minute pembrolizumab infusions: a prospective cohort study. *JCO Oncol Pract* 2025. https://doi.org/10.1200/OP-25-00918
3. Tran JH, Brunk KM and Martin GA. Infusion-related reactions associated with nivolumab and pembrolizumab: a case series analysis. *J Hematol Oncol Pharm* 2026;16(3):1-7.

Gemcitabine in D5W to Reduce Vein Irritation

Gemcitabine is classified as an irritant in the BC Cancer Extravasation Hazard Table. Available evidence suggests that dilution in **D5W**, rather than NS, **reduces vein irritation when gemcitabine is administered by peripheral IV infusion**. Gemcitabine is compatible with both solutions. An optional concurrent administration of D5W solution may further reduce irritation (similar to oxaliplatin protocols).

BC Cancer has implemented the following updates in all IV gemcitabine-containing treatment protocols, PPPOs and Cerner PowerPlans:

- gemcitabine diluent has changed from NS to D5W
- for moderate vascular pain during gemcitabine peripheral administration, an optional concurrent D5W infusion is available

Drug Update

References:

1. Hosokawa A, Nakashima T, Ogawa Y, et al. Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately. *J Oncol Pharm Pract* 2013;19(2):190-192. https://doi.org/10.1177/1078155212449679
2. Nagai H, Kitano T, Nishimura T, et al. Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study. *Support Care Cancer* 2013;21(12):3271-3278. https://doi.org/10.1007/s00520-013-1901-9
3. Uchiyama K, Saito Y, Sakamoto T, et al. A 5% glucose solution for the liquid formulation gemcitabine solvent decreases gemcitabine-induced vascular pain. *Anticancer Res* 2022;42(1):343-348. https://doi.org/10.21873/anticanres.15491

Etoposide Capsule Storage

Supply constraints for the etoposide 50 mg capsule have led Health Canada to authorize the importation of United States supply over the next several months. Details about storage conditions include:

- storage instructions in the product labelling differ between Canadian (20-25°C, room temperature) and US (2-8°C, refrigerator) products
- as the imported supply arrives, products labelled with different storage requirements may be available concurrently at BC Cancer regional centres for a period of time
- the manufacturer has confirmed that the Canadian-marketed etoposide capsule, although labelled for room temperature storage, also has stability data supporting refrigerator storage without affecting the quality or the shelf life of the product

For ease of operationalization, BC Cancer has made the decision to move **all etoposide 50 mg capsule stock**, regardless of storage conditions on product labelling, to **refrigerator storage**.

The Cancer Drug Manual© etoposide monograph, etoposide (oral) patient handout and Auxiliary Label List, as well as applicable protocol patient handouts, have been updated to reflect etoposide storage in the refrigerator.

Practice Standards and Policies

All Systemic Therapy policies and procedures are on the BC Cancer page of **Shared Health Organizations Portal (SHOP)**.

Dose Banding Update: Paclitaxel NAB

Over the past year, BC Cancer has introduced dose banding for a number of drugs, with standardized dose bands being integrated into protocols, PPPOs and the Cerner system. By standardizing doses within the acceptable dose variance specified in **Systemic Therapy Policy III-10: Systemic Therapy Treatment Delivery Process**, dose banding minimizes the need to open extra vials for small dose adjustments. This approach reduces drug wastage, allowing for significant cost avoidance.

Drug volume of individual vials is an important consideration in determining dose bands. In practice, withdrawal of the full labelled volume is not always possible. **Paclitaxel NAB** dose bands have been updated as of **01 November 2026**; this update is a result of consistent feedback on the extractable volume from paclitaxel NAB vials. Please note:

- affected treatment protocols and PPPOs have been updated; these dosing banding updates do not impact Cerner PowerPlans
- **Dose Banding Tables** for all dose banding-approved drugs are posted in the Cancer Drug Manual© Appendix
- the **durvalumab** dose banding update is planned for **01 December 2026**

Cancer Drug Manual©

All documents are available in the **Cancer Drug Manual©** on the BC Cancer website.

New Documents

The **Inavolisib Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Nathalie Levasseur (medical oncologist, BC Cancer Breast Tumour Group) and Jelena Mucovic (tumour group pharmacist representative, BC Cancer Provincial Pharmacy). Inavolisib is an orally administered kinase inhibitor that targets the phosphatidylinositol 3-kinase (PI3K) pathway. It is used in combination with palbociclib and fulvestrant in the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more *PIK3CA* mutations. The usual dose is 9 mg once daily.

Highlights from these documents include:

- blood glucose should be optimized prior to starting treatment
- diarrhea occurs frequently and prompt initiation of loperamide is recommended
- reduced starting dose is recommended in patients with moderate to severe renal impairment

Inavolisib has been added to the **Auxiliary Label List** and evaluated for the **BC Health Authorities Provincial Hazardous Drug List.**

Note that the following drugs are not BC Cancer Benefit Drugs and require application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monographs and Chemotherapy Preparation and Stability Chart entries are made available for reference only.

The **Balstilimab** and **Botensilimab Interim Monographs** have been developed. **Balstilimab** is a programmed cell death 1 (PD-1) checkpoint inhibitor. The usual fixed dose of 240 mg is given intravenously once every 2 weeks. **Botensilimab** is a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) checkpoint inhibitor. The usual fixed dose of 75 mg is given intravenously once every 6 weeks. Balstilimab and botensilimab are used in combination for the treatment of colorectal cancer, and are only available via the Health Canada Special Access Program.

Highlights from these documents include:

- immune-mediated adverse events are managed with treatment interruption and corticosteroids; refer to SCIMMUNE for details
- infusion-related reactions are rare, but can be severe; consider premedication in patients with prior infusion-related reactions
- dose reductions are not recommended

Balstilimab and **botensilimab** have been added to the **Chemotherapy Preparation and Stability Chart** and evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Cancer Drug Manual©

Revised Documents

Epcoritamab Monograph, Patient Handout and Chemotherapy Preparation and Stability Chart

Uses: updated
Side Effects table: added hemophagocytic lymphohistiocytosis (HLH) and progressive multifocal leukoencephalopathy (PML)
Side Effects paragraphs: added paragraphs on HLH and PML
Solution Preparation and Compatibility: added step-up dose 3
Dosage Guidelines: updated dosing information with step-up dose 3
Patient Handout:
Side Effects table: updated wording for nervous system problems
Emergency help bullets: updated bullet for nervous system problems
As soon as possible bullets: moved bullet for bruising
Chemotherapy Preparation and Stability Chart: new entry for step-up dose 3

Etoposide Monograph and Patient Handout (Oral)

Supply and Storage: added Amneal Pharmaceuticals and Onesource Specialty Pharma brands for etoposide capsule (temporary importation for drug shortage)
Patient Handout (*Storage* bullet): revised to remove "store at room temperature" recommendation and updated with "refrigerate"

Gemcitabine Monograph and Chemotherapy Preparation and Stability Chart

Side Effects table: updated references for extravasation
Side Effects paragraphs: updated paragraph on injection site reactions with information that dilution in D5W may reduce vein irritation
Supply and Storage: deleted Accord brand
Chemotherapy Preparation and Stability Chart
Product column: bolded D5W; deleted Accord brand

Goserelin Monograph and Patient Handout

Special Precautions > Pregnancy: updated paragraph; clarified that goserelin should not be relied on as the sole method of contraception
Patient Handout
Throughout: updated with current template wording
Allergic reaction bullet: removed buserelin
Birth control bullet: updated wording with "non-hormonal method" of birth control

Leuprolide Monograph and Patient Handout

Special Precautions > Pregnancy: updated paragraph; clarified that goserelin should not be relied on as the sole method of contraception
Patient Handout
Throughout: updated with current template wording
Allergic reaction bullet: removed buserelin
Birth control bullet: updated wording with "non-hormonal method" of birth control

Pembrolizumab Monograph

Parenteral Administration: updated intermittent infusion duration (bolded and italicized 10 minutes)

Cancer Drug Manual©

Auxiliary Label List

The **Auxiliary Label List** has been updated:

Etoposide: added "keep in refrigerator" label
Inavolisib: added to the list

Extravasation Hazard Table

Amivantamab, **nivolumab-relatlimab**, **tremelimumab** and **zolbetuximab** have been added to the **Extravasation Hazard Table**. Vindesine has been removed from the table.

Lactose Intolerance: Approach to Dispensing Oral Medications

The flow chart **Approach to Dispensing Oral Medications for Patients with Lactose Intolerance** has been posted in the Cancer Drug Manual© Appendix. This resource was developed to assist pharmacists when dispensing oral oncology medications to patients with lactose intolerance or when patients report gastrointestinal symptoms and are concerned about the lactose content in their medications. A review of the lactose content of oral medications found that:

- the amount of lactose contained as an excipient in tablets and capsules is much lower than the amount most patients with lactose intolerance can tolerate
- adverse drug reactions (ADRs) or medical conditions are more likely to cause gastrointestinal symptoms than lactose intolerance

Given the limited clinical impact of lactose content in oral oncology medications, and the significant resources required to maintain up-to-date lactose content information in Cancer Drug Manual© (CDM) documents, the CDM team has started phasing out information on the lactose content of oral oncology medications from existing CDM monographs and patient handouts.

Additionally, a newly developed **Pharmacy FAQ** provides more detail into the following questions:

- What is lactose intolerance?
- Does excipient lactose cause lactose intolerance symptoms?
- How much lactose can people with lactose intolerance tolerate?
- How much lactose in is oral oncology medications?
- What additional factors should be considered (nocebo effect)?
- How can I help lactose intolerant patients when they start a new medication containing lactose?
- How do I know if a patient is experiencing lactose intolerance symptoms or gastrointestinal ADRs?

Reference:

Wanbon L, Badry N and de Lemos ML. Lactose intolerance or gastrointestinal adverse drug effect? guidance for oncology pharmacists. *J Oncol Pharm Pract* 2025;31:1316-1322. https://doi.org/10.1177/10781552251352203

Continuing Education

FPON | Managing Menopause in Patients with Hormone-Sensitive Cancers

The Family Practice Oncology Network (FPON) is pleased to announce a webinar entitled **Managing Menopause in Patients with Hormone-Sensitive Cancers: Practical Strategies for Primary Care**, with Dr. Kerstin Gustafson. The webinar is Thursday 19 November 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Explain how treatment of hormone-sensitive cancers, such as breast, ovarian, and endometrial cancer, contributes to menopausal symptoms
- Recognize and assess menopausal symptoms in patients with a history of hormone-sensitive cancer
- Apply management strategies for these menopausal symptoms
- Integrate practical resources to aid in decision-making and patient education

For more information and link to registration, visit:
FPON Webinar | Managing Menopause in Patients with Hormone-Sensitive Cancers | UBC CPD

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer **Benefit Drug List** effective 01 November 2026:

Protocol Title	Protocol Code	Benefit Status
Therapy of Advanced Breast Cancer using **Inavolisib**, **Palbociclib** and **Fulvestrant** with or without LHRH Agonist	**UBRAVIPBFL**	Restricted
Second-Line Treatment of Advanced Esophageal and Gastroesophageal Junction Squamous Cell Carcinoma using Weekly **Paclitaxel**	**GIGAVTW**	Class I
Alternative Treatment of Cervical Cancer using **Bevacizumab**, **Carboplatin** and **Paclitaxel NAB**	**GOCXCPNB**	Class I
Alternative Treatment of Ovarian Cancer using **Bevacizumab**, **Carboplatin** and **Paclitaxel NAB**	**GOOVCPNB**	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U.**

NEW Protocols, PPPOs and Patient Handouts *(new documents checked ☑)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJPEM6	Adjuvant Treatment of Resected Triple-Negative Breast Cancer using 6-Weekly Pembrolizumab	☐	☐	☑
UBRAVIPBFL	Therapy of Advanced Breast Cancer using Inavolisib, Palbociclib and Fulvestrant with or without LHRH Agonist	☑	☑	☐
GIGAVTW	Second-Line Treatment of Advanced Esophageal and Gastroesophageal Junction Squamous Cell Carcinoma using Weekly Paclitaxel	☑	☑	☐
GOCXCPNB	Alternative Treatment of Cervical Cancer using Bevacizumab, Carboplatin and Paclitaxel NAB	☑	☑	☐
GOOVCPNB	Alternative Treatment of Ovarian Cancer using Bevacizumab, Carboplatin and Paclitaxel NAB	☑	☑	☐
SAIME	Etoposide, Ifosfamide and Mesna (SAIME) for Use in Sarcomas	☐	☑ *New inpatient PPPO on BC Cancer website*	☐

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR | Breast				
BRAJPEM	Adjuvant Treatment of Resected Triple-Negative Breast Cancer using Pembrolizumab	*Eligibility, treatment, pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
BRAJPEM6	Adjuvant Treatment of Resected Triple-Negative Breast Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*New patient handout created*
BRAJPN	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB, Carboplatin and Trastuzumab	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJPNT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using Paclitaxel NAB	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
UBRAVCAFLV	Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant with or without LHRH Agonist	*Eligibility and exclusions updated*	---	---
BRAVEVEX	Therapy for Advanced Breast Cancer using Everolimus and Exemestane	*Eligibility updated*	---	---
BRAVGEM	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine	*Gemcitabine bag diluent, administration, contact information and references updated; eligibility and tests clarified*	*Gemcitabine bag diluent and administration updated*	---
BRAVGEMD	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and Docetaxel	*Gemcitabine bag diluent, administration, contact information and references updated; eligibility and tests clarified*	*Gemcitabine bag diluent and administration updated; tests clarified*	---
BRAVGEMP	Palliative Therapy for Metastatic Breast Cancer using Cisplatin and Gemcitabine	*Gemcitabine bag diluent, administration, contact information and references updated; eligibility and tests clarified*	*Gemcitabine bag diluent and administration updated; tests clarified*	---
BRAVGEMT	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and Paclitaxel	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated; tests clarified*	---
BRAVLUENH	Palliative Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	*Eligibility and exclusions clarified*	---	---
BRAVPALAI	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist	*Eligibility updated*	---	---
BRAVPBFLV	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	*Eligibility updated*	---	---
BRAVPEM	Treatment of Metastatic Breast Cancer using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAVPEM6	Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	---
BRAVPGC	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine and Carboplatin	*Pembrolizumab infusion duration, gemcitabine bag diluent, administration and references updated*	*Pembrolizumab infusion duration, gemcitabine bag diluent and administration updated*	*Treatment and side effects updated*
BRAVPP	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with Paclitaxel	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
BRAVPPN	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and Paclitaxel NAB	*Pembrolizumab infusion duration, paclitaxel NAB dose banding table and references updated*	*Pembrolizumab infusion duration and paclitaxel NAB dose banding table updated*	*Treatment and side effects updated*
BRAVRBFLV	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	*Eligibility updated*	---	---
BRAVRIBAI	Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with or without LHRH Agonist	*Eligibility updated*	---	---
BRLACPNAC	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRLACPNACG	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRLAPNAC	Alternative Neoadjuvant Therapy for Locally Advanced Breast Cancer using Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRLAPNACG	Alternative Neoadjuvant Therapy for Breast Cancer using Dose Dense Therapy: Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
BRPCTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab with Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRPCWTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab, Weekly Carboplatin and Weekly Paclitaxel, Followed by Doxorubicin and Cyclophosphamide	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
CN | Neuro-Oncology				
UCNVORA	Therapy for Grade 2 Astrocytoma or Oligodendroglioma with IDH-1 or IDH-2 Mutation using Vorasidenib	*Exclusion criteria updated*	---	---
GI | Gastrointestinal				
GIAVDURPG	First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
GIAVPEM	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
GIAVPEM6	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
GIAVPEMPG	First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum	*Pembrolizumab infusion duration, gemcitabine bag diluent, administration and references updated*	*Pembrolizumab infusion duration, gemcitabine bag diluent, administration and return appointment orders updated*	---
GIAVPG	First-Line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum	*Gemcitabine bag diluent, administration, dose modifications and references updated; contact information clarified*	*Gemcitabine bag diluent and administration updated*	---
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin, and Trastuzumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIGAVPFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	---
GIPAJGCAP	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine	*Gemcitabine bag diluent, administration and references updated; contact information clarified*	*Gemcitabine bag diluent and administration updated*	---
GIPAJGEM	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma using Gemcitabine	*Eligibility, gemcitabine bag diluent, administration and references updated; contact information clarified*	*Gemcitabine bag diluent and administration updated*	---
GIPGEM	Palliative Chemotherapy for Pancreatic Adenocarcinoma, Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine	*Gemcitabine bag diluent, administration and references updated; eligibility and contact information clarified*	*Gemcitabine bag diluent and administration updated*	---
GIPGEMABR	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB and Gemcitabine	*Paclitaxel NAB dose banding table, gemcitabine bag diluent, administration and references updated*	*Paclitaxel NAB dose banding table, gemcitabine bag diluent and administration updated*	---
GO | Gynecologic Oncology				
GOCABR	Alternative Treatment of Gynecological Malignancies using Carboplatin and Paclitaxel NAB	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
GOCABRBEV	Alternative Treatment of Gynecologic Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB	*Note added for eligibility; paclitaxel NAB dose banding table updated*	*Disclaimer note added; paclitaxel NAB dose banding table updated*	---
GOCXCPNBP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, Carboplatin, Paclitaxel NAB and Pembrolizumab	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
GOCXCPNP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Carboplatin, Paclitaxel NAB, and Pembrolizumab	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
GOEAVDPNC	Alternative Treatment of Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOEAVPPNC	Alternative Treatment of Advanced or Recurrent Endometrial Cancer using Pembrolizumab, Paclitaxel NAB and Carboplatin	*Paclitaxel NAB dose banding table updated*	*Paclitaxel NAB dose banding table updated*	---
GOOVBEVG	Platinum-Resistant or -Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
GOOVCAG	Treatment of Advanced Ovarian Cancer in Patients Who Have Progressed or Recurred Following First-line Platinum-Based Treatment using Carboplatin and Gemcitabine	*Gemcitabine bag diluent, administration and references updated; Cockcroft-Gault equation clarified*	*Gemcitabine bag diluent and administration updated*	---
GOOVGEM	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Gemcitabine	*Eligibility, gemcitabine bag diluent, administration and references update*	*Gemcitabine bag diluent and administration updated*	---
GOSADG	Treatment of Uterine Sarcoma Cancer using Docetaxel and Gemcitabine	*Eligibility, tests, gemcitabine bag diluent, administration and references updated; dose modifications and units of measure clarified*	*Gemcitabine bag diluent, administration and tests updated; units of measure clarified*	---
GU | Genitourinary				
GUAJPEM	Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---
GUAJPEM6	Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	---
GUAJPG	Adjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	*Contact information, gemcitabine bag diluent, administration and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; tests and units of measure clarified*	---
GUAVEVPEM	First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Enfortumab Vedotin and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---
GUAVPEM	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUAVPEM6	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
GUAVPEMAX	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Axitinib	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
GUAVPEMAX6	Treatment of Metastatic Renal Cell Carcinoma using 6-Weekly Pembrolizumab and Axitinib	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
GUAVPEML	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---
GUAVPEML6	Treatment of Metastatic Renal Cell Carcinoma using 6-Weekly Pembrolizumab and Lenvatinib	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	---
GUAVPG	Palliative Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	*Contact information, gemcitabine bag diluent, administration and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; tests and units of measure clarified*	---
GUBGEM	Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine	*Contact information and eligibility updated; tests clarified*	*Minor formatting*	---
GUBGEMDOC	Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel	*Contact information and eligibility updated; tests clarified*	*Minor formatting*	---
GUBGRT	Treatment of Muscle-Invasive Urothelial Cancer using Gemcitabine and Radiation Therapy	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
GUBNADURPG	Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer using Durvalumab, Platinum and Gemcitabine	*Gemcitabine bag diluent, administration and references updated; units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure clarified*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUNAJPG	Neo-Adjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	*Gemcitabine bag diluent, administration, contact information and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; tests and units of measure clarified*	---
UGUPLVT	Treatment of Metastatic Castration Resistant Prostate Cancer using Lutetium (177Lu) Vipivotide Tetraxetan (PLUVICTO)	*CAP requirement for treatment delay updated*	---	---
GUTAXGEM	Palliative Therapy for Germ Cell Cancers using Paclitaxel and Gemcitabine	*Contact information, gemcitabine bag diluent, administration and references updated; eligibility, tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; tests and units of measure clarified*	---
HN | Head and Neck				
HNNAVGEM	Treatment of Loco-Regionally Recurrent/ Metastatic Nasopharyngeal Cancer not Amenable for Local Curative Therapy with Gemcitabine	*Eligibility, contact information, gemcitabine bag diluent, administration and references updated; units of measure and tests clarified*	*Gemcitabine bag diluent and administration updated; tests clarified*	---
HNNAVPG	Treatment of Locoregionally Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Gemcitabine	*Eligibility, contact information, gemcitabine bag diluent, administration and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated*	---
HNNLAPG	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine	*Contact information, eligibility, gemcitabine bag diluent, administration and references updated; units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure clarified*	---
LK | Leukemia and BMT				
LKCMLA	Treatment of Chronic Myeloid Leukemia using Asciminib	*Eligibility updated*	---	---
LKCMLB	Treatment of Chronic Myeloid Leukemia using Bosutinib	*Eligibility and exclusions updated*	---	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LKCMLD	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Dasatinib	*Eligibility and exclusions updated; dose modifications clarified*	---	---
LKCMLN	Treatment of Chronic Myeloid Leukemia using Nilotinib	*Eligibility and exclusions updated*	---	---
LU | Lung				
LUAJPMB	Adjuvant Treatment of Non-Small Cell Lung Cancer using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	---
LUAJPMB6	Adjuvant Treatment of Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	---
LUAVPCPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
LUAVPG	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine	*Contact information, eligibility, gemcitabine bag diluent, administration and references updated; units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure clarified*	---
LUAVPGCEM	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Cemiplimab	*Gemcitabine bag diluent, administration and references updated; units of measure clarified*	**Cycles 1 to 6 PPPO** *Gemcitabine bag diluent and administration updated; units of measure clarified* **Cycles 7+ PPPO** *Minor formatting*	---
LUAVPGDT	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (NSCLC) with Platinum, Gemcitabine, Durvalumab and Tremelimumab	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
LUAVPGPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	*Pembrolizumab infusion duration, gemcitabine bag diluent, administration and references updated; treatment and dose modification tables clarified*	*Pembrolizumab infusion duration, gemcitabine bag diluent and administration updated*	**2 PPPOs** *Treatment and side effects updated*

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUAVPMB	Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
LUAVPMB6	Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
LUAVPMBF	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
LUAVPMBF6	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
LUAVPMBM	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated; tests clarified*	*Treatment and side effects updated*
LUAVPMBM6	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with 6-Weekly Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration and return appointment orders updated*	*Treatment and side effects updated*
LUAVPPMBM	Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	*Treatment and side effects updated*
LUAVPPPMB	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	*Pembrolizumab infusion duration updated*	**2 PPPOs** *Treatment and side effects updated*
LUMMPG	Treatment of Malignant Mesothelioma with Platinum and Gemcitabine	*Contact information, eligibility, gemcitabine bag diluent, administration and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure clarified*	---
LUMMPPPMB	Treatment of Malignant Mesothelioma using Platinum, Pemetrexed and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	**Cycles 1 to 6 PPPO** *Pembrolizumab infusion duration updated* **Cycles 7+ PPPO** *Pembrolizumab infusion duration and return appointment orders updated*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUNAPGPMB	Neoadjuvant-Adjuvant Treatment of Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	*Pembrolizumab infusion duration, gemcitabine bag diluent, administration and references updated; units of measure clarified*	**Neoadjuvant phase** *Pembrolizumab infusion duration, gemcitabine bag diluent and administration updated; units of measure clarified* **Adjuvant phase** *Pembrolizumab infusion duration and return appointment orders updated*	---
LUNAPPPMB	Neoadjuvant-Adjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed, Platinum and Pembrolizumab	*Pembrolizumab infusion duration and references updated*	**Neoadjuvant and Adjuvant Phase PPPOs** *Pembrolizumab infusion duration updated*	---
LUSCPEPO	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Oral Etoposide	---	---	**2 PPPOs** *Etoposide storage updated*
LUSCPEPORT	Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	---	---	**2 PPPOs** *Etoposide storage updated*
LUSCPOE	Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide	---	---	*Etoposide storage updated*
LY | Lymphoma				
LYBV	Consolidation Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma using Brentuximab Vedotin	*Eligibility updated*	---	---
LYDHAPR	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and Rituximab	*Eligibility clarified*	---	---
LYGDP	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum	*Contact information, eligibility, gemcitabine bag diluent, administration and references updated; units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure clarified*	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYGDPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and Obinutuzumab	*Contact information, gemcitabine bag diluent, administration and references updated; units of measure clarified*	**Induction Cycle 1 and Cycles 2 to 6 PPPOs** *Gemcitabine bag diluent and administration updated; units of measure clarified*	---
LYGDPR	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with Rituximab	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
LYGEMOXPEG	Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
LYGVLD	Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
ULYOGGEMOX	Treatment of Lymphoma using Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin	*Gemcitabine bag diluent, administration and references updated*	**Cycle 1 and Cycles 2 to 8 PPPOs** *Gemcitabine bag diluent and administration updated*	---
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	*Eligibility clarified*	---	---
MY | Myeloma				
UMYTEC	Treatment of Relapsed and Refractory Multiple Myeloma using Teclistamab	*Dose modifications updated*	---	---
SA | Sarcoma				
SAAVGEM	Advanced Soft Tissue Sarcoma using Gemcitabine	*Gemcitabine bag diluent, administration and references updated*	*Gemcitabine bag diluent and administration updated*	---
SAAVGEMD	Therapy for Soft Tissue Sarcomas using Gemcitabine and Docetaxel	*Contact information, gemcitabine bag diluent, administration and references updated; tests and units of measure clarified*	*Gemcitabine bag diluent and administration updated; units of measure and tests clarified*	---
SAAVVIT	Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Irinotecan	*Treatment table updated*	---	---

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SAAVVPOIT	Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Oral Irinotecan	*Treatment table updated*	---	---
SAIME	Etoposide, Ifosfamide and Mesna (SAIME) for Use in Sarcomas	*Eligibility, tests and units of measure clarified; contact information and dose modifications updated*	**Outpatient PPPO** *PPPO title updated; tests and treatment clarified; urine dipstick instructions and return appointment orders updated* **Inpatient PPPO** *New PPPO created*	---
SM | Skin and Melanoma				
SMAJDT	Adjuvant Treatment of Stage III and IV, BRAF Mutated, Fully Resected Melanoma using Dabrafenib and Trametinib	---	*Supply instructions and tests clarified*	---
SMAVDAB	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Dabrafenib	---	*Supply instructions clarified*	
SMAVIPNI	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	*Nivolumab bag size updated*	**Induction PPPO** *Nivolumab bag size updated*	---

Resources and Contact Information

Resource	Phone	Email / Toll Free
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	druginfo@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	please email	cap_bcca@bccancer.bc.ca
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	please email	oscar@bccancer.bc.ca
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623	mlin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Mário de Lemos, PharmD, MSc(Oncol)
Alina Gerrie, MD, MPH, FRCPC
Yuna Jang, RN
Michelle Lafreniere, BScN, RN
Alison Pow, BScPharm